Mechanisms of NSCLC EGFR-mutant Cell Lines Developing Treatment-Adaptive Resistance In vitro
DOI:
https://doi.org/10.61173/jpeg5g65Keywords:
EGFR-TKI resistance, non-small cell lung cancer, HIF-1αAbstract
NSCLC ranks at the top of lung carcinoma cases worldwide, with three generations of EGFR-TKIs used in clinics where resistance derives ultimately. Molecular mechanisms have been underscored for their contribution to resistance. More recent studies reported the first-line therapy Osimertinib gives rise to the acquired T790M and C797S mutations, addressing the necessity of inhibitor usage. Therapeutic windows occur by the lung-specific hydroxylase mimicry and pVHL agonists development for HIF-1α high-accuracy degradation, considering the correlation between HIF-1α and other signaling pathways. This paper analyzed the in vitro research on the role of MAPK and PI3K-Akt pathway, NF-κB pathway, and hypoxia-regulated HIF-1α signaling in generating EGFR-TKI resistance and obtained the results of further validation in the inhibitors used for the pathways blockage. The pathways involved trigger the hallmarks of cancer and stimulate inflammation under stressed conditions. Meanwhile, inhibitors failed in their function due to misleading signal engagement, technical weakness, and off-target effects. With new target emergence, it drives a potential of constant disruption in resistance-associated pathways. However, the target feasibility and practical drug development pipeline have not been revealed and require future studies.
References
[1] Fu K., Xie FC., Wang F., et al. Therapeutic strategies [15]Ichihara E., Westover D., Meador CB., et al. SFK/FAK for EGFR-mutated non-small cell lung cancer patients with Signaling Attenuates Osimertinib Efficacy in Both Drugosimertinib resistance. Journal of Hematology & Oncology, Sensitive and Drug-Resistant Models of EGFR-Mutant Lung 2022, 15(1). Cancer. Cancer Research, 2017, 77(11): 2990-3000.
[2] Chmielecki J., Gray JE., Cheng Y., et al. Candidate [16]Zhang X., Maity TK., Ross KE., et al. Alterations in the mechanisms of acquired resistance to first-line osimertinib in Global Proteome and Phosphoproteome in Third Generation EGFR-mutated advanced non-small cell lung cancer. Nature EGFR TKI Resistance Reveal Drug Targets to Circumvent Communications, 2023, 14(1). Resistance. Cancer Research, 2021, 81(11): 3051-3066.
[3] Chen CJ., Liu YP. MERTK Inhibition: Potential as a [17]Liu YN., Tsai MF., Wu SG., et al. miR-146b-5p Enhances Treatment Strategy in EGFR Tyrosine Kinase Inhibitor-Resistant the Sensitivity of NSCLC to EGFR Tyrosine Kinase Inhibitors Non-Small Cell Lung Cancer. Pharmaceuticals, 2021, 14(2). by Regulating the IRAK1/NF-B Pathway. Molecular Therapy-
[4] Eberlein CA., Stetson D., Markovets AA., et al. Acquired Nucleic Acids, 2020, 22: 471-483. Resistance to the Mutant-Selective EGFR Inhibitor AZD9291 [18]Huang JX., Zhuang C., Chen J., et al. Targeted Drug/Gene/ Is Associated with Increased Dependence on RAS Signaling in Photodynamic Therapy via a Stimuli-Responsive Dendritic- Preclinical Models. Cancer Research, 2015, 75(12): 2489-2500. Polymer-Based Nanococktail for Treatment of EGFR-TKI-
[5] Wang LH., Dong XY., Ren Y., et al. Targeting EHMT2 Resistant Non-Small-Cell Lung Cancer. Advanced Materials, reverses EGFR-TKI resistance in NSCLC by epigenetically 2022, 34(27). regulating the PTEN/AKT signaling pathway. Cell Death & [19]Sooy RA., Han JY., Dafni U., et al. A randomised phase II Disease, 2018, 9. study of osimertinib and bevacizumab versus osimertinib alone
[6] Seguin LJ., Kato S., Franovic A., et al. 3 integrin/KRAS/ as second-line targeted treatment in advanced NSCLC with RalB complex drives tumor stemness and resistance to EGFR confirmed EGFR and acquired T790M mutations: the European inhibition. Cancer Research, 2014, 74(19). Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial.
[7] Blakely CM., Pazarentzos E., Olivas,V., et al. NF-B- Annals of Oncology, 2022, 33(2): 181-192. Activating Complex Engaged in Response to EGFR Oncogene [20]Westover D., Zugazagoitia J., Cho BC., et al. Mechanisms Inhibition Drives Tumor Cell Survival and Residual Disease in of acquired resistance to first- and second-generation EGFR Lung Cancer. Cell Reports, 2015, 11(1): 98-110. tyrosine kinase inhibitors. Annals of Oncology, 2018, 29:
[8] Kane LP., Stokoe D., Weiss A. Induction of NF-B by the Akt I10-I19. PKB kinase. Current Biology,1999, 9(11): 601-604. [21]Wang SH., Song YP., Liu DL. EAI045: The fourth-
[9] Rotow J., Bivona TG. Understanding and targeting resistance generation EGFR inhibitor overcoming T790M and C797S mechanisms in NSCLC. Nature Reviews Cancer, 2017, 17(11): resistance. Cancer Letters, 2017, 385: 51-54. 637-658. [22]Tang YY., Wang DC., Wang YQ., et al. Emerging role
[10] Meng SY., Wang GR., Lu Y., et al. Functional cooperation of hypoxia-inducible factor-1 in inflammatory autoimmune between HIF-1 and c-Jun in mediating primary and acquired diseases: A comprehensive review. Frontiers in Immunology, resistance to gefitinib in NSCLC cells with activating mutation 2023, 13. of EGFR. Lung Cancer, 2018, 121: 82-90. [23]Li PF., Sun Q., Bai SP., et al. Combination of the cuproptosis
[11] Hu H., Miao XK., Li JY., et al. YC-1 potentiates the inducer disulfiram and anti-PD-L1 abolishes NSCLC resistance antitumor activity of gefitinib by inhibiting HIF-1 and promoting by ATP7B to regulate the HIF-1 signaling pathway. International the endocytic trafficking and degradation of EGFR in gefitinib- Journal of Molecular Medicine, 2024, 53(2).
Downloads
Published
Issue
Section
License
Copyright (c) 2024 by the authors.
This work is licensed under a Creative Commons Attribution 4.0 International License.
